Complementary SGLT2 Inhibitor Plus GLP-1 Agonist Therapy in Type 2 Diabetes
This narrative review synthesizes randomized and observational evidence supporting combined SGLT2 inhibitor and GLP-1 receptor agonist use, offering a phenotype-guided framework that Endocrinology and Obesity pharmacists can apply to cardiometabolic risk stratification.
Combining SGLT2is and GLP-1RAs may revolutionize diabetes management.
Combining sodium-glucose cotransporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) in type 2 diabetes may optimize cardiometabolic outcomes through complementary mechanisms. SGLT2is reduce heart failure hospitalizations and slow kidney disease progression, while GLP-1RAs reduce atherosclerotic events, especially stroke, with benefits retained regardless of background therapy. The study supports a phenotype-guided use of combined therapy in patients with type 2 diabetes and multiple high-risk comorbidities, offering a personalized treatment approach. Combination SGLT2i and GLP-1RA therapy provides additive benefits in cardiometabolic risk management for type 2 diabetes.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.